Inhibitors, Agonists, Screening Libraries
www.MedChemExpress.com
Data Sheet
Product Name:Cat. No.:CAS No.:
Molecular Formula:Molecular Weight:Target:Pathway:Solubility:
SDMAHY-10141030344-00-4C8H18N4O2202.25OthersOthers
DMSO: 8.33 mg/mL
BIOLOGICAL ACTIVITY:
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity.
In Vitro: SDMA is the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of
renal function. SDMA does not directly inhibit NOS but is a competitor of arginine transport. SDMA is primarily eliminated by renalin intact endothelial cells, whereas it has no effect on protein expression of NOS[1]. SDMA is involved in the inflammatory processof chronic kidney disease, activating NF–κB and resulting in enhanced expression of IL–6 and TNF–α[2].
excretion and is a promising endogenous marker of glomerular filtration rate[1]. SDMA inhibits dose dependently the NO synthesis
In Vivo: SDMA is highly stable in serum and plasma, and the assay demonstrates excellent analytical performance. In unaffected
dogs, SDMA remains unchanged whereas in affected dogs, SDMA increases during disease progression, correlating strongly withdid not change at 4 weeks. No histological changes are observed, particularly no effect on fibrosis or endothelias nitric oxidesynthase expression. There is neither an effect of SDMA on systolic blood pressure nor on ejection fraction[4].
an increase in sCr and decrease in GFR[3]. Chronic SDMA infusion leads to a significant increase of SDMA levels in mice, but the GFR
PROTOCOL (Extracted from published papers and Only for reference)
Cell Assay:[2]SDMA stock solution is prepared in 0.9% NaCl and diluted in the cell culture medium or in heparinized whole bloodresulting in a maximal uremic concentration of 6.1 μM SDMA. Whole blood is incubated with saline (control) or different doses ofADMA (0.6, 3.6, and 36 μM) or SDMA (1.5, 3.1, and 6.1 μM) for 2 hours in a humidified atmosphere of 5% CO2 in air at 37°C. Cellsare finally stained for intracellular TNF–α or IL–6. Samples are analyzed with a flow cytometer[2].
Animal Administration:[4]Mouse: Eight–week–old male C57Bl/6 mice receives vehicle–controlled infusion of SDMA (250
μmol/kg/days) for 28 days using osmotic minipumps (n=24/group). Glomerular filtration rate, cardiac function and blood pressureare monitored. Blood samples for SDMA determination are obtained at baseline, 2 and 4 weeks. Mice are euthanized at 4 weeks toobtain tissue for renal histology[4].
References:
[1]. Bode–B?ger SM,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent ofcoronary artery disease.
[2]. Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2374–83.[3]. Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the EarlyDetection of Chronic Kidney Disease inDogs. J Vet Intern Med. 2015 Jul–Aug;29(4):1036–44.
[4]. Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice.Nephrol Dial Transplant. 2013 Jun;28(6):1434–9.
www.MedChemExpress.com
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-68 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
www.MedChemExpress.com
